Wyeth

Oscient Pharmaceuticals Corporation

Wei Liu

Leeying Wu

Paul John Yaworsky

Lynette A Fouser

Kristina Allen

Christopher Todd Brown

Jimin Zhang

Ching-Hsiung Frederick Lo

Stephane Olland

Anthony Anisowicz

Zhijian Lu

Bradley A Ozenberger

James R Graham

Arturo Morales

Emily Sheng-Ming Shen

Huimin Chen

Roger Ford

Xiaobing Be

Bijia Deng

Steven A Haney

Hemchand Sookdeo

Jee Hyung Lee

Members of the TGF-&#x3b2; superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics.

Finger-1 peptide analogs of the TGF-&#x3b2; superfamily

The invention provides isolated protein kinase polypeptides related to novel brain-localized protein kinases homologous to known homeodomain-interacting protein kinases (HIPKs), isolated nucleic acid molecules that encode these polypeptides, inhibitors, and methods related thereto. The novel polypeptides and nucleic acid molecules of the invention are termed HIPK4. The invention also provides genetically engineered expression vectors, host cells, and transgenic animals comprising the novel nucleic acid molecules of the invention. The invention additionally provides antisense and RNAi molecules to the nucleic acid molecules of the invention, as well as inhibitors, activators, and antibodies capable of binding to the protein kinase polypeptides of the invention. The invention further provides uses of HIPK4 and its inhibitors, e.g., mutants of HIPK4 lacking protein kinase activity, for modulation of apoptosis, as well as the prevention and treatment of neurological disorders and cancers.

Methods of modulating apoptosis using inhibitors of brain-localized protein kinases homologous to homeodomain-interacting protein kinases

The present invention relates to methods and materials used to express an HBM-like polypeptide derived from HBM, LRP5 or LRP6 in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the HBM-like polypeptides. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development and lipid modulation. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

HBM variants that modulate bone mass and lipid levels

This invention provides compositions, organisms and methodologies employing a novel human protein kinase, HPK3P23. The novel human kinase has sequence homology to the catalytic domains of several protein kinases. The gene encoding this novel protein kinase is localized in or near the 3p23 locus of the human chromosome 3. The sequence similarity between the novel human protein and the catalytic domain of protein kinases indicates that the novel human protein may function as a protein kinase.

Compositions, organisms and methodologies employing a novel human kinase

This invention provides compositions, organisms and methodologies employing a novel human protein kinase, MCRK1. The novel human kinase has sequence homology to rat myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK) alpha. The gene encoding the novel kinase is localized in locus 11q13 of human chromosome 11. The novel protein kinase comprises multiple functional/structural domains that include a kinase domain, a pkinase_C domain, a DAG-PE binding domain, and a CNH domain. The sequence and structure similarity between the novel human protein and rat MRCK alpha indicates that the novel human protein may function as a downstream effector of Cdc42 in cytoskeleton reorganization.

Composition employing a novel human kinase

This invention provides compositions, organisms and methodologies employing a novel human gene encoding a protein that has sequence homology to a consensus sequence of calcineurin-like phosphoesterase family are disclosed. The novel protein is encoded by a human gene comprising 4 exons. The human gene is localized in the 10p15 locus of human chromosome 10. The sequence similarities between the novel human protein and the consensus sequence of calcineurin-like phosphoesterases indicate that the novel human protein may function as a calcineurin-like protein phosphatase.

Compositions employing a novel human protein phosphatase

The present invention provides novel isolated CRF2-12 polynucleotides and polypeptides encoded by the CRF2-12 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-12 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-12 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the CRF2-12 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

Type 2 cytokine receptor and nucleic acids encoding same

Compositions employing a novel human kinase

Growing community of inventors

Sudbury, MA, United States of America

Wei Liu